D
Dimitris Mavridis
Researcher at University of Ioannina
Publications - 170
Citations - 9203
Dimitris Mavridis is an academic researcher from University of Ioannina. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 34, co-authored 137 publications receiving 6862 citations. Previous affiliations of Dimitris Mavridis include World Bank & Paris School of Economics.
Papers
More filters
Journal ArticleDOI
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht,Andrea Cipriani,Andrea Cipriani,Loukia M. Spineli,Dimitris Mavridis,Deniz Örey,Franziska Richter,Myrto Samara,Corrado Barbui,Rolf R. Engel,John R. Geddes,Werner Kissling,Marko Paul Stapf,Bettina Lässig,Georgia Salanti,John M. Davis +15 more
TL;DR: A Bayesian-framework, multiple-treatments meta-analysis of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia found all drugs were significantly more effective than placebo.
Journal ArticleDOI
Graphical tools for network meta-analysis in STATA
TL;DR: This paper provides a set of STATA routines that can be easily employed to present the evidence base, evaluate the assumptions, fit the network meta-analysis model and interpret its results.
Journal ArticleDOI
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors
Stefan Leucht,Claudia Leucht,Maximilian Huhn,Anna Chaimani,Dimitris Mavridis,Bartosz Helfer,Myrto Samara,Matteo Rabaioli,Susanne Bächer,Andrea Cipriani,John R. Geddes,Georgia Salanti,John M. Davis +12 more
TL;DR: Almost twice as many patients improved with antipsychotics as with placebo, but only a minority experienced a good response, and drug development may benefit from smaller samples but better-selected patients.
Journal ArticleDOI
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Suetonia C. Palmer,Dimitris Mavridis,Dimitris Mavridis,Antonio Nicolucci,David W. Johnson,David W. Johnson,Marcello Tonelli,Jonathan C. Craig,Jasjot K. Maggo,Vanessa Gray,Giorgia De Berardis,Marinella Ruospo,Patrizia Natale,Valeria Saglimbene,Sunil V. Badve,Sunil V. Badve,Yeoungjee Cho,Annie-Claire Nadeau-Fredette,Michael Burke,Michael Burke,Labib Faruque,Anita Lloyd,Nasreen Ahmad,Yuanchen Liu,Sophanny Tiv,Natasha Wiebe,Giovanni F.M. Strippoli,Giovanni F.M. Strippoli +27 more
TL;DR: Findings are consistent with American Diabetes Association recommendations for using metformin monotherapy as initial treatment for patients with type 2 diabetes and selection of additional therapies based on patient-specific considerations.
Journal ArticleDOI
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis
Suetonia C. Palmer,Dimitris Mavridis,Eliano Pio Navarese,Jonathan C. Craig,Marcello Tonelli,Georgia Salanti,Natasha Wiebe,Marinella Ruospo,David C. Wheeler,Giovanni F.M. Strippoli,Giovanni F.M. Strippoli +10 more
TL;DR: A network meta-analysis of randomised trials from around the world comparing blood pressure-lowering agents in adults with diabetic kidney disease found ACE inhibitors and ARBs, alone or in combination, were the most effective strategies against end-stage kidney disease.